These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Feasibility and oncological safety of sentinel node biopsy in breast cancer patients with a local recurrence. Biglia N, Bounous VE, Gallo M, Fuso L, Sgro LG, Maggiorotto F, Ponzone R. Breast; 2018 Oct; 41():8-13. PubMed ID: 29933180 [Abstract] [Full Text] [Related]
25. Does the presence of sentinel lymph node macrometastases in breast cancer patients require axillary lymph node dissection?-Single-center analysis. Nowikiewicz T, Zegarski W, Pagacz K, Nowacki M, Morawiec-Sztandera A, Głowacka-Mrotek I, Sowa M, Biedka M, Kołacińska A. Breast J; 2018 Sep; 24(5):724-729. PubMed ID: 29476570 [Abstract] [Full Text] [Related]
30. [Preliminary study on a new sentinel lymphoscintigraphy agent 99mTc-Rituximab for breast patient]. Wang XJ, Lin BH, Yang Z, Ouyang T, Li JF, Xu B, Zhang Y, Zhang MY. Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):200-3. PubMed ID: 16875605 [Abstract] [Full Text] [Related]
34. Role of number of sentinel nodes in predicting non-sentinel node metastasis in breast cancer. Dong LF, Xu SY, Long JP, Wan F, Chen YD. J Int Med Res; 2018 Feb; 46(2):828-835. PubMed ID: 29441833 [Abstract] [Full Text] [Related]
35. Discordance between number of scintigraphic and perioperatively identified sentinel lymph nodes and axillary tumour recurrence. Volders JH, van la Parra RF, Bavelaar-Croon CD, Barneveld PC, Ernst MF, Bosscha K, De Roos WK. Breast; 2014 Apr; 23(2):159-64. PubMed ID: 24456968 [Abstract] [Full Text] [Related]